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A B S T R A C T
The objective of this study was to determine prognostic factors related to death from adult tetanus. Fifty-
three cases of tetanus, 25 females and 28 males, were treated in C¸ukurova University Hospital during
1994–2000. The mean age was 46.6 years. Forty-one (77.7%) patients came from rural areas. Most
(64.1%) cases had minor trauma, but 19 (35.8%) had deep injuries. The mean incubation period was
11.5 days. Mortality was high (52.8%), caused by cardiac or respiratory failure or complications, and
was related to the length of the incubation period. In cases with an incubation period £ 7 days, the
mortality rate was 75% (p 0.07). Mortality was significantly associated with generalised tetanus
(p < 0.05), fever of ‡ 40 C, tachycardia of > 120 beats ⁄min (p < 0.05), post-operative tetanus (p 0.03),
and the absence of post-traumatic tetanus vaccination (p 0.068). Patients who were given tetanus human
immunoglobulin or tetanus antiserum (p > 0.05) had similar outcomes. Patients who were given
penicillin had a mortality rate similar to patients who were given metronidazole (p 0.15). The mortality
rate was higher (92%) in patients with severe tetanus than in patients with moderate disease (53%). By
multivariate analysis, the time to mortality caused by tetanus, and also the mortality rate, were both
related significantly to age and tachycardia.
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I N T R O D U C T I O N
Tetanus cases and deaths caused by tetanus have
decreased to a great extent as a result of immu-
nisation programmes [1,2]. However, although
effective and inexpensive tetanus vaccines are
available, the disease remains a continuing health
problem, causing high mortality and morbidity in
developing countries [3–5]. In developed coun-
tries, 59% of all reported tetanus cases and 85% of
all reported deaths caused by tetanus occur
among people aged ‡ 60 years [6,7]. The elderly
are susceptible because many have not received
primary immunisation or the recommended boos-
ter immunisation [2,6,8,9]. In contrast, most
deaths from tetanus in developing countries are
seen in neonates [10].
Neonatal deaths caused by tetanus in Turkey
have been reduced significantly as a result of
tetanus immunisation programmes for pregnant
women, but the mortality rate of neonatal tetanus
in rural areas is c. 40% [10]. Expanded immuni-
sation programmes have been recommended for
elimination of neonatal tetanus in Turkey [11], but
the study of Maral et al. [12] found that nearly
53% of pregnant women had not been vaccinated
[12]. Moreover, considerably more rural women
than urban women were vaccinated. One study
conducted in Turkey found protective levels of
tetanus antitoxin in 69% of the population, with a
haemagglutination concentration of > 0.125 haem-
agglutination U ⁄mL being considered as protect-
ive [13]. However, tetanus remains an important
health problem in Turkey because of the large
number of traffic and work accidents, extensive
agricultural activity, and abortion and ⁄ or delivery
under non-hygienic conditions. Adult tetanus is
seen in Turkey because injured people do not apply
to heath institutions for prophylaxis.
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In spite of modern medical care, the death rate
among patients with generalised tetanus is still
high (20%) [14–16]. Mortality can be influenced
by a patient’s age, the incubation time, type of
injury, clinical signs, and delays in treatment or
prophylaxis [17]. The aim of this study was to
determine the important prognostic factors asso-
ciated with deaths from adult tetanus in the
eastern Mediterranean region of Turkey.
M E T H O D S A N D P A T I E N T S
In total, 53 tetanus patients admitted to the Infectious Diseases
Department of C¸ukurova University Hospital (Adana, Turkey)
between January 1994 and July 2000 were investigated retro-
spectively and were followed for 60 days if they survived.
C¸ukurova University Hospital is a tertiary-care hospital with
860 beds and admits c. 28 000 patients annually for treatment.
Tetanus patients were admitted to the hospital from other
hospitals in the region. Patient data recorded were age, sex,
disease localisation, type of injury, incubation time, onset of
first symptoms, history of tetanus immunisation, post-trauma
tetanus prophylaxis, clinical signs, mode of treatment, and
complications. All patients were given benzodiazepine (dia-
zepam 5 mg ⁄kg) and, when needed, chlorpromazine and
muscle relaxants for control of tonic–clonic contractions.
Mechanical ventilation was used when generalised spasms
were not controlled. Tracheostomy and ⁄or mechanical venti-
lation were also used in patients who had respiratory prob-
lems. All patients received passive immunisation with human
immunoglobulin (HIG) 4000–10 000 U, or tetanus antiserum
60 000–100 000 U, and active immunisation with tetanus tox-
oid. After admission, patients were followed for up to
2 months.
In addition to individual prognostic factors, the value of
Wood’s scoring scheme [17] prognosis was investigated, with
one point being assigned for each of the following: incubation
period < 7 days; period of onset < 2 days; acquired following
burns, surgery, septic abortion, surgical wound or compound
fracture; generalised tetanus; fever of > 40 C; tachycardia of
> 120 beats ⁄min; and narcotic addiction.
Chi-squared tests or, when needed, Fisher’s exact test were
used to analyse the association between mortality and categ-
orical variables such as gender, incubation period, tetanus
type, etc. In evaluating the prognostic value of the scoring
scheme of Wood [17], the trend test of Cochran and Armitage
[18] was employed. In addition, the fatality rate among tetanus
patients was examined by multivariate logistic regression
models, which included variables of incubation period and
symptoms simultaneously.
R E S U L T S
Of the 53 patients, 28 (52.8%) were male and 25
were female, with a mean age of 46.6 years
(range: 20–75 years). Forty-one (77.3%) patients
came from rural areas and 12 from urban areas,
and no drug use among patients was reported.
Most (64.1%) of the cases had minor trauma, but
19 (35.8%) had deep injuries. Nine (16.8%)
patients developed tetanus after traffic accidents,
two (3.8%) after an operation, one (1.9%) after a
non-hygienic injection, two (3.8%) after com-
pound fractures, two (3.8%) after septic abortion,
two (3.8%) following non-hygienic delivery, and
35 (66%) after acute injury associated with foreign
objects.
Thirteen (24.5%) patients had symptoms for
> 2 days before hospital admission, but only three
patients had a period of < 2 days between the first
symptom and the first spasm. Most (79.2%)
patients had generalised contractions, while
11 (20.7%) patients only had trismus on admission.
However, six of these patients developed general-
ised contractions during the follow-up period.
The mean incubation period was 11.5 days
(range: 2–40 days); 12 (22.6%) patients had an
incubation period of £ 7 days, and 41 (77.3%) had
an incubation period of > 7 days. Eleven (20.7%)
patients had head and neck injuries, 40 (75.5%)
had injuries on extremities, and two (3.8%) had
injuries on the torso. Before admission, 15 (28.3%)
patients had received only one dose of tetanus
vaccine, and 38 (71.7%) had not received primary
tetanus vaccination. After trauma, tetanus immu-
nisation was not administered to 32% of the
patients. None received tetanus immunoglobulin
at the time of trauma, but 43 (81.1%) received
tetanus HIG (4000–10 000 U) on admission to
hospital, while the remaining ten patients were
given 60 000–100 000 U of anti-tetanus serum.
Both groups of patients experienced similar mor-
tality. During therapy, 22 (41.5%) patients had a
tracheostomy, and seven (13.2%) were mechanic-
ally ventilated.
Among the total of 53 cases, 22.6% were mild,
52.8% were moderate, and 24.6% had severe
clinical tetanus. Mild cases were given only
sedation; moderate cases were given a tracheos-
tomy plus sedation; and mechanical ventilation
plus sedation was given to severe cases when
generalised spasm was not controlled (7 ⁄ 13).
Nosocomial infection was seen in 14 (26.4%)
patients. The fatality rate among all patients with
tetanus was 52.8%. The causes of death were
cardiac arrest in 16 patients, arrhythmia in two
patients, respiratory failure in eight patients, and
nosocomial infections in two patients. The rela-
tionship between mortality and prognostic factors
for tetanus is shown in Table 1. Mortality was
related to the length of the incubation period. The
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fatality rate among cases with an incubation
period of £ 7 days was higher (75%) than among
the cases with an incubation period of > 7 days
(p 0.07). Mortality was significantly associated
with generalised tetanus (p < 0.05), fever of
‡ 40 C, tachycardia of > 120 beats ⁄min (p < 0.05),
post-operative tetanus, post-injection tetanus,
septic abortion (p 0.03), and the absence of post-
trauma tetanus vaccination (p 0.068). Patients
given tetanus HIG or tetanus antiserum showed
similar outcomes (p > 0.05). Patients who were
given penicillin had a fatality rate similar to that
of patients who were given metronidazole
(p 0.148). The fatality rate was higher among
cases with severe tetanus (92%) than among
moderate cases (53%). There was a trend in
fatality rates as the Wood score increased; it was
lower (8%) among patients with a score of 1,
moderate (53%) among patients with a score of
2–3, and highest (92%) among patients with score
of ‡ 4 (p < 0.002). The binary logistic model
revealed that the existence of tachycardia and
an age > 60 years were simultaneously the most
significant prognostic risk factors in relation to
mortality among tetanus patients (Table 2).
D I S C U S S I O N
The World Health Organisation has reported that
tetanus is seen in one million people ⁄year, and
that > 715 000 ⁄ year die from tetanus or its com-
plications [19]. Most cases of tetanus in developed
countries occur among adults who were either not
immunised or were immunised inadequately.
Despite the higher rate of tetanus in men than in
women in other studies [2,20,21], the patients in
Table 1. The relationship between mortality and prognos-
tic factors for tetanus
Total (n)
Fatality
p valuesn Rate (%)
Total number of patients 53 28 52.8
Age (years)
< 60 35 16 45.7 0.12
‡ 60 18 12 66.7
Sex
Male 28 17 60.7 0.17
Female 25 11 44
Reasons for tetanus
Post-traumatic 46 21 45.6 0.03
Post-surgery 7 7 100
Place of wound
Head or face 11 5 45.4 0.23
Extremities 40 21 52.5
Trunk 2 2 100
Incubation period
£ 7 day 12 9 75.6 0.07
> 7 day 41 19 46.3
Patients who had
received one dose
of tetanus vaccine
Yes 15 7 46.7 0.4
No 38 21 55.3
Tetanus vaccine
after trauma
Yes 36 16 44.4 0.068
No 17 12 70.6
Types of tetanus
Generalised 48 28 58.3 0.00
Local 5 0 0
Fever
‡ 40 C 26 19 73 0.006
< 40 C 27 9 33.3
Pulse
‡ 120 ⁄min 31 22 71 0.002
< 120 ⁄min 22 6 27.3
Nosocomial infection
Yes 14 9 64.3 0.24
No 39 19 48.7
Therapy
Penicillin 40 19 47.5 0.14
Metronidazole 13 9 69.2
Wood Prognostic Score
0–1 12 1 8.3 0.000
2–3 28 15 53.6 Cochran
–Armitage test
‡ 4 13 12 92.3
Table 2. Results of binary logistic
regression analysis, with fatality rate
as a response variable Variables
Regression
coefficient Standard error Significance (p)
Relative
risk (RR)
95% CI for RR
Lower Upper
Age 1.707 0.840 0.042 5.513 1.062 28.629
Incubation period
< 7 days 1.469 0.962 0.127 4.345 0.659 28.645
> 7 days (reference) 1.0
Treatment with
Metronidazole 1.371 0.815 0.092 3.939 0.798 19.440
Penicillin (reference) 1.0
Tachycardia
‡ 120 ⁄min 1.999 0.735 0.007 7.385 1.748 31.206
120 ⁄min (reference) 1.0
Tetanus vaccine
given after trauma
No 1.015 0.761 0.183 2.759 0.621 12.267
Yes (reference) 1.0
Constant ) 2.520 0.835 0.003 0.080
CI, confidence interval.
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the present study did not differ by gender,
probably because most came from rural areas
where women work as much as men in agricul-
tural activities.
The incidence of tetanus depends on the social
environment, season, climate and soil [22]. Tet-
anus can be seen in all seasons in the eastern
Mediterranean region of Turkey, because of the
sub-tropical climate and an agricultural society.
The prognosis for tetanus depends on additional
nosocomial infections, immunisation, other dis-
ease, disease severity, and delay in treatment [22].
Debridements and wound care after injury are
also important for prevention of tetanus after
injury, and this was not done properly for most of
the cases in the present study. In other studies, the
mortality rate ranges from 28% to 48% [21–23],
but was 52.8% in the study reported here. Unlike
other studies [2,7,21], no significant difference by
gender was observed, and mortality rates did not
differ significantly between those aged ‡ 60 years
(67%) and those aged < 60 years (46%; p 0.12),
however, this might be a result of insufficient
numbers of patients aged ‡ 60 years for compar-
ison.
There is an important reported difference in the
fatality rate among patients with an incubation
period of < 7 days compared to > 7 days [21,24],
and a similar observation was made in the present
study (p 0.07). Mortality was high in patients with
generalised tetanus, with high fever, or with
tachycardia, and in patients who had devel-
oped tetanus after injection or surgery, with an
incubation period of < 7 days. Other studies have
reported high mortality rates in patients with an
incubation period of < 7 days with generalised
tetanus, as well as in those developing tetanus
after abortion, post-injection, or with penetrating
injuries [17,19,21]. Patients who were initially
given tetanus antiserum or tetanus HIG did not
show different mortality rates (p 0.2), which is
similar to the findings of Patel and Mehtra [21]. It
has also been reported that mortality is higher
among patients given penicillin than among
patients using metronidazole [25], but there was
no difference in the present study.
The absence of primary immunisation is one
of the most important risk factors in the devel-
opment of tetanus. According to the Centers for
Disease Control [2], 95% of affected patients
have not completed primary immunisation,
while the rest will have received no immunisa-
tion. When the immunity of the patients with
tetanus in the present study was evaluated,
absence of primary immunisation, or the admin-
istration of only one dose of vaccine, were
among the most important mortality risk factors.
In this study, there was no significant difference
in mortality between those vaccinated with one
dose and those never vaccinated (p 0.40), while
32% of the patients did not receive post-trauma
tetanus vaccine because they did not attend a
health centre after trauma had occurred. It has
been shown in Turkey that 97.4% of patients
who complete primary vaccination have anti-
bodies 5 years after the last vaccine dose, com-
pared with 53% of those with incomplete
primary vaccination [26]. In another study,
20% of those aged > 50 years were reported to
have immunity against tetanus in Turkey [13]. In
the present study, there was a trend towards
increased mortality with an increasing Wood
score, indicating a need to classify the severity
and prognosis of disease on admission to hos-
pital.
In conclusion, because of the high risk of death
among patients, tetanus continues to be an
important public health problem, even though it
is preventable by vaccination. The Immunization
Practices Advisory Committee of the Centers for
Disease Control recommends a primary immuni-
sation programme, with booster shots every
10 years [27]. The results of the present study
suggest that there is insufficient adult immunisa-
tion and use of tetanus boosters in Turkey. As a
result, it is essential that widespread campaigns
of adult immunisation are started. In particular,
those who live in rural areas should be well-
informed and educated about the need to consult
health service personnel after trauma because of
the risk of developing tetanus.
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